Ista Pharmaceuticals (Products Now Under Bausch + Lomb, Which Was Acquired By Valeant)

ISTA Pharmaceuticals, Inc, was a rapidly growing specialty pharmaceutical company developing, marketing and selling products in the U.S. and Puerto Rico. It was the fourth largest branded prescription eye care business in the U.S. and had an emerging allergy drug franchise. Its products treated ocular inflammation and pain, glaucoma, dry eye and ocular allergies. It had a U.S. sales force of more than 165 representatives calling on ophthalmologists, optometrists and allergists. The four key products included: • BROMDAY™ (bromfenac ophthalmic solution) 0.09% for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extractions • BEPREVE® (bepotastine besilate ophthalmic solution) 1.5% for the treatment of ocular itching associated with allergic conjunctivitis • ISTALOL® (timolol maleate ophthalmic solution) 0.05% for the treatment of glaucoma • VITRASE® (hyaluronidase injection) ovine, 200 USP units/ml for use as a spreading agent In June of 2012, ISTA was acquired by Bausch + Lomb and now operates under the Pharmaceutical business of Bausch + Lomb. In July of 2013, Bausch + Lomb was acquired by Valeant.